The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2017 | What is the best treatment regimen for MM?
Laurent Garderet, MD, from Hopital Saint-Antoine, Paris, France, talks to us about the complexity of current treatments for multiple myeloma (MM) due to the availability of doublet and triplet drug combinations. He notes that generally for relapsed MM patients, a triplet regimen, usually RVD (revlimid-velcade-dexamethasone) is the gold-standard treatment, although a subset of patients may not benefit from this regimen. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
